ODT Market To Exceed $13 Billion By 2015
The market for orally disintegrating and fast dissolving tablets could exceed revenues of $13 billion by 2015 based on upward global growth trends, according to a report from Technology Catalysts.
The market for orally disintegrating and fast dissolving tablets could exceed revenues of $13 billion by 2015 based on upward global growth trends, according to a report from Technology Catalysts. The report explains that ODTs and oral thin films (OTFs) have continued to expand as dysphagia, patient compliance and consumer convenience issues receive increased attention.
As a result, the combined EU, Japanese and US ODT market doubled in size during the past 4 years and exceeded $6 billion in 2009. Its market value has also been bolstered by the increase in generic competition. According to the report, there are now more than 450 available commercial OTC and prescription ODT products, partly thanks to the introduction of generic formulations and an increase in the number of generic manufacturers. Additionally, brand companies are also looking for new innovative and differentiating concepts.
New OTC OTFs are also being commercialized in the US to expand into markets such as pain management and motion sickness, which demand faster onset of action. More than 80 OTF brands have been launched in North America since 2003 and the market is well positioned for further growth.
“More importantly, prescription OTFs have now been approved in all three major regions (US, EU and Japan),” explains the report summary. “These approved Rx films, along with several key molecules in the OTF pipelines, have potential to canibalize other oral dosage forms of the same drugs.”
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
